We just received data on a new analyst forecast for $PCRX. Serge Belanger from Needham set a price target of 32.0 for PCRX.
To track analyst ratings and price targets for $PCRX, check out Quiver Quantitative's $PCRX forecast page.
Should you buy $PCRX?
Some analysts are better than others. To view the past performance of Needham, check out Quiver’s Analyst Ratings dashboard. You can also see Quiver’s Analyst Buys Strategy, which uses a proprietary method to track the companies being recommended by the top Wall Street analysts.
$PCRX Price Targets
Multiple analysts have issued price targets for $PCRX recently. We have seen 4 analysts offer price targets for $PCRX in the last 6 months, with a median target of $30.0.
Here are some recent targets:
- Serge Belanger from Needham set a target price of $32.0 on 05/01/2026
- Glen Santangelo from Barclays set a target price of $25.0 on 03/26/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $38.0 on 01/09/2026
- Les Sulewski from Truist Securities set a target price of $28.0 on 11/07/2025
$PCRX Insider Trading Activity
$PCRX insiders have traded $PCRX stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $PCRX stock by insiders over the last 6 months:
- SHAWN CROSS (Chief Financial Officer) has made 0 purchases and 7 sales selling 62,060 shares for an estimated $1,521,350.
- KRISTEN WILLIAMS (Chief Administrative Officer) sold 13,137 shares for an estimated $269,702
- JONATHAN SLONIN (Chief Medical Officer) has made 0 purchases and 2 sales selling 7,221 shares for an estimated $169,812.
- LAUREN RIKER (Senior Vice President, Finance) has made 0 purchases and 2 sales selling 5,416 shares for an estimated $117,563.
- MARK FROIMSON sold 500 shares for an estimated $10,905
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$PCRX Revenue
$PCRX had revenues of $177.4M in Q1 2026. This is an increase of 5.0% from the same period in the prior year.
You can track PCRX financials on Quiver Quantitative's PCRX stock page.
$PCRX Hedge Fund Activity
We have seen 122 institutional investors add shares of $PCRX stock to their portfolio, and 125 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BALYASNY ASSET MANAGEMENT L.P. removed 939,092 shares (-49.8%) from their portfolio in Q4 2025, for an estimated $24,303,700
- CITADEL ADVISORS LLC added 748,590 shares (+1051.7%) to their portfolio in Q4 2025, for an estimated $19,373,509
- JACOBS LEVY EQUITY MANAGEMENT, INC removed 482,105 shares (-73.9%) from their portfolio in Q4 2025, for an estimated $12,476,877
- ASSENAGON ASSET MANAGEMENT S.A. removed 435,143 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $9,834,231
- VANGUARD GROUP INC removed 384,612 shares (-7.4%) from their portfolio in Q4 2025, for an estimated $9,953,758
- HILLSDALE INVESTMENT MANAGEMENT INC. added 308,200 shares (+inf%) to their portfolio in Q4 2025, for an estimated $7,976,216
- UBS GROUP AG removed 296,210 shares (-34.7%) from their portfolio in Q4 2025, for an estimated $7,665,914
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
